All In MedTech

FDA Clearance Tracker · P080032

ALAIR BRONCHIAL THERMOPLASTY SYSTEM

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 20, 2026Latest source record: Apr 27, 2010 (this decision)Source: openFDAMethods & limitations

PMAFirst of its product code

Decided

Apr 27, 2010

Approved

Time to decision

483 days

Received Dec 30, 2008. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P080032
Device name
ALAIR BRONCHIAL THERMOPLASTY SYSTEM
Applicant location
Sunnyvale, CA
Received
Dec 30, 2008
Decided
Apr 27, 2010
Decision
Approved
Expedited review
Yes, flagged as expedited in FDA's record.
Supplements
20 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III

Every decision under product code OOY

FDA's approval statement

As written in FDA's record.

APPROVAL FOR THE ALAIR BRONCHIAL THERMOPLASTY SYSTEM. THE DEVICE IS INDICATED FOR THE TREATMENT OF SEVERE PERSISTENT ASTHMA IN PATIENT 18 YEARS AND OLDER WHOSE ASTHMA IS NOT WELL CONTROLLED WITH INHALED CORTICOSTEROIDS AND LONG ACTING BETA AGONISTS.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • This is the earliest decision in FDA's data under product code OOY (Bronchial thermoplasty system).
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Boston Scientific Corp

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.